ABSI
Absci Corporation
Absci (ABSI) Q2 2026 earnings
Published Aug 11, 2026
AI summary
- Revenue $318K, down 46% from $593K a year ago.
- GAAP EPS −$0.21 missed the −$0.20 consensus by $0.01, up from −$0.24 a year ago.
- Revenue for the second quarter of 2026 was $0.3 million, down from $0.6 million in the prior year period.
- The company reported a net loss of $33.2 million for the quarter, compared to a $30.6 million loss a year ago.
- Absci completed a $100 million underwritten offering, including a $40 million investment from Eli Lilly.
Results vs analyst consensus
Revenue
Reported
$318K
Consensus not captured before release
−46% YoY
EPS · GAAP (street basis)
Reported · Diluted EPS (GAAP, street basis)
−$0.21
Consensus −$0.20
Missed by $0.01GAAP EPS: −$0.21
Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- Research and development expenses increased to $22.6 million due to internal program advancements.
- The company is currently in the clinical-stage and has not yet generated significant commercial revenue.
Read original report
Source: Absci Corporation press release · SEC Form 8-K exhibit 99.1